Oral LP-168 for relapsed or hard-to-treat B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 1 study tests whether an oral medicine called LP-168 can be given safely and possibly work against lymphoma that has come back or is not responding to standard treatment. It’s mainly looking for safety, but your results could help determine whether the drug should be studied further.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have B-cell lymphoma that has relapsed or not responded, such as DLBCL or FL (after 2 prior standard treatment lines) or certain other B-cell lymphomas (after 1 prior line)
- You have enough bone marrow, liver, and kidney function for study treatment
- You can take the study drug by mouth and agree to regular checkups and tests
- If you can become pregnant or father a child, you must use reliable birth control during the study
- You have not had certain other lymphomas (like Burkitt lymphoma) and not had a post-transplant lymphoma condition
- You have not had certain recent treatments (like chemotherapy/targeted therapy/immunotherapy) or recent major procedures or radiation
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called LY4152199 for people with certain types of lymphoma (follicular or diffuse large B-cell) that came back or didn't respond to previous treatment. The goal is to see if the drug is safe and how well it works.
This trial tests a new drug, GLB-002, for people with non-Hodgkin lymphoma that has come back or hasn't responded to other treatments. The goal is to see if GLB-002 is safe and whether it can help shrink or control the lymphoma.
This Phase 1 trial studies LP-168 taken by mouth in people whose B-cell cancers have come back or did not respond to treatment. The study aims to find how the drug works, the right dose, and what side effects to expect.
This Phase 1 study tests an oral (by mouth) drug called LP-118 in people whose blood cancers have returned or did not respond to prior treatment. The goal is to find a safe dose and see whether it can shrink or control the cancer.
This trial tests an experimental drug called LP-284 in people with certain advanced lymphomas or solid tumors that have not responded to standard treatments. The goal is to see if it is safe and works against these cancers.
This early-stage study tests a new medicine (BGB-16673) that targets B-cell cancer cells in people with specific lymphoma or related blood cancers. It aims to see how well the drug can control the cancer and what side effects it causes, especially in Chinese participants.
Hear when a new Lymphoma, B-Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.